cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.57760/sciencedb.j00001.01040
title: Data set of seawater quality monitoring information 2017-2023
title: 2017-2023年海水水质监测信息数据集

description: Based on the data of Bohai Sea, Yellow Sea, East China Sea and South China Sea released by the Seawater Quality Monitoring Information Disclosure System of Ministry of Ecology and Environment, PRC in the past seven years, the 2017-2023 seawater quality monitoring information dataset was prepared. Data set Vector data of seawater quality monitoring and summary table of seawater quality monitoring are saved in gdb and xls formats respectively. The dataset contains 16 fields such as object code, vector type, sea area, province, city, point code, measured longitude, measured latitude, monitoring time, pH, dissolved oxygen, chemical oxygen demand, inorganic nitrogen, active phosphate, petroleum, and water quality. This data has the characteristics of comprehensive data, long time span, good quality and diverse field types.
description: Based on the data of Bohai Sea, Yellow Sea, East China Sea and South China Sea released by the Seawater Quality Monitoring Information Disclosure System of Ministry of Ecology and Environment, PRC in the past seven years, the 2017-2023 seawater quality monitoring information dataset was prepared. Data set Vector data of seawater quality monitoring and summary table of seawater quality monitoring are saved in gdb and xls formats respectively. The dataset contains 16 fields such as object code, vector type, sea area, province, city, point code, measured longitude, measured latitude, monitoring time, pH, dissolved oxygen, chemical oxygen demand, inorganic nitrogen, active phosphate, petroleum, and water quality. This data has the characteristics of comprehensive data, long time span, good quality and diverse field types.
DOI: 10.57760/sciencedb.08650
title: test-改投社区3
title: test-改投社区3

description: test-改投社区3
description: test-改投社区3
DOI: 10.5281/zenodo.5646624
title: reduced permeability

description: # permeability reduction Matlab scripts to simulate the reduced permeability of porous granular media due to ice or hydrate. The functions are organized in two classes, including:<br> - `soil.m`. Calculate the soil freezing curves using a Monte Carlo method on synthetic soil models.<br> - `frw.m`. Calculate the permeabilities of the synthetic soil models, ice-free or ice-bearing, and compare the results against published models and measurements.<br> - `duct.m`. Examples showing the calculations in straight ducts of simple cross-sections. Parameters and data for calculations are in:<br> - `param.json`. All relevant parameters.<br> - `data/conductivity.xlsx`. Digitized measurements used for validation.<br> - `data/kr_finney.mat`. Simulated permeability reduction of Finney pack.<br> - `data/mc`. Simulated Monte Carlo results to calculate the soil freezing curves.<br> - `data/deposit`. Synthetic soil models, including the mono-dispersed Finney pack, and poly-dispersed synthetic soil. For details of the code, refer to the paper *Estimating permeability of partially frozen soil using floating random walks* published in Water Resources Research. This repository can also be found on GitLab.
DOI: 10.57760/sciencedb.13972
title: optinoal数据发布测试
title: optinoal数据发布测试

description: optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试
description: optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试optinoal数据发布测试
DOI: 10.5281/zenodo.1065122
title: Tail-Seq For Zebrafish Early Embryos Injected With Control Or Tut4/7 Morpholinos (Internal Id: Hs31, Part 8/10)

description: This dataset contains the raw sequencing data from a TAIL-seq run for zebrafish embryos. The cluster intensities of fluorescence signals are repacked as an HDF5 formatted file, then split into multiple parts to fit in the dataset size limitation of the Zenodo.
DOI: 10.5281/zenodo.3935321
title: Dataset of gas permeability and flux simulation of poplar tension wood

description: The datasets generated during the study &lt;Relationship between pore structure and gas permeability in poplar (<em>Populus deltoides</em> CL.'55/65') tension wood&gt;.
DOI: 10.5281/zenodo.3946943
title: ODP Leg 174B, Hole 395A - Well Logging Data

description: Logging data are measurements of physical properties of the formation surrounding a borehole, acquired in situ after completion of coring (wireline logging) or during drilling (Logging-While-Drilling, LWD). The range of data (resistivity, gamma radiation, velocity, density, borehole images,…) in any hole depends on the scientific objectives and operational constraints.
description: ODP Leg 174B: CORK Hole 395A
DOI: 10.5281/zenodo.4146803
title: Supplymented Data for "On the Conditions of Aliasing Effects in Constellations with More than Four Spacecraft"

description: Supplymented Data for "On the Conditions of Aliasing Effects in Constellations with More than Four Spacecraft"
DOI: 10.5281/zenodo.4399603
title: 基于系统模型的用户评论中非功能需求的自动分类

description: 以下是“基于系统模型的用户评论中非功能需求的自动分类 ”文献提供的数据包.包含本研究使用的数据集(供其他研究人员使用).同时, 我们提供了对数据集进行描述的文件. <strong>1. Dataset文件夹</strong> <em>dataset_user_reviews.xlsx</em>文件包含1278条已经分类的非功能需求用户评论:行为型需求和表示型需求. <em>readme.txt</em> 文件详细描述了<em>dataset_user_reviews.xlsx</em> 中各列数据的含义.
DOI: 10.5281/zenodo.4542543
title: The updated dataset of figures for "The GPU version of LICOM3 under HIP framework and its large-scale application"

description: A high-resolution (1/20°) global ocean general circulation model with Graphics processing units (GPUs) code implementations is developed based on the LASG/IAP Climate system Ocean Model version 3 (LICOM3) under Heterogeneous-compute Interface for Portability (HIP) framework. The dynamic core and physics package of LICOM3 are both ported to the GPU, and 3-dimensional parallelization is applied. The HIP version of the LICOM3 (LICOM3-HIP) is 42 times faster than the same number of CPU cores when 384 AMD GPUs and CPU cores are used. The LICOM3-HIP has excellent scalability; it can still obtain a speedup of more than four on 9216 GPUs comparing to 384 GPUs. In this phase, we successfully performed a test of 1/20° LICOM3-HIP using 6550 nodes and 26200 GPUs, and at the grand scale, the model’s time to solution can still obtain an increasing, about 2.72 simulated years per day (SYPD). The high performance was due to putting almost all of the computation processes inside GPUs, reducing the time cost of data transfer between CPUs and GPUs. Simultaneously, a 14-year spin-up integration following phase 2 of the Ocean Model Intercomparison Project (OMIP-2) protocol of surface forcing has been conducted, and the preliminary results have been evaluated. We found that the model results have little difference from the CPU version. Further comparison with observations and lower-resolution LICOM3 results suggests that the 1/20° LICOM3-HIP can reproduce the observations and produce many smaller-scale activities, such as submesoscale eddies and frontal scales structures.
DOI: 10.5281/zenodo.4626242
title: Data accompanying the research on reservoir operation for the Pong and Bhakra reservoir in Northern India

description: This dataset contains time series of reservoir releases (including any spills), evaporation loss, and rule curves for the Pong and Bhakra reservoirs, India.
description: {"references": ["https://doi.org/10.3390/w11071413", "https://doi.org/10.1016/j.scitotenv.2019.06.021"]}
DOI: 10.5281/zenodo.4662103
title: COVID-KG-CreationData

description: All of the data used for the construction of the COVID-19 KG. This included identifier mapping from ChEMBl, ChEBi and DrugBank to InChi Keys as well as the mapping from UniProt to Entrez identifiers.
DOI: 10.5281/zenodo.5636634
title: Shapefile

description: Shapefile with vectors subsets
DOI: 10.5281/zenodo.5666329
title: 中国湖泊

description: 中国1平方公里以上湖泊shape数据
DOI: 10.5281/zenodo.6549862
title: AQI-Data

description: The hourly observations of the near-surface mass concentrations of PM<sub>2.5</sub>, O<sub>3</sub>, NO<sub>2</sub>, SO<sub>2</sub>, and CO in China form May to June in 2018 released by the Ministry of Ecology and Environment of China.
DOI: 10.5281/zenodo.6549863
title: AQI-Data

description: The hourly observations of the near-surface mass concentrations of PM<sub>2.5</sub>, O<sub>3</sub>, NO<sub>2</sub>, SO<sub>2</sub>, and CO in China form May to June in 2018 released by the Ministry of Ecology and Environment of China.
DOI: 10.5281/zenodo.6815258
title: Zhengzhou dataset

description: Zhengzhou dataset
DOI: 10.57760/sciencedb.08649
title: test-改投社区2
title: test-改投社区2

description: test-改投社区2
description: test-改投社区2
DOI: 10.15468/dl.z8jbnn
title: Occurrence Download

description: A dataset containing 1880 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Mycteroperca phenax Jordan & Swain, 1884",
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 "Year is greater than or equal to 1900"
 ]
}

 The dataset includes 1880 records from 62 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0053634-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.jfzvvm
title: Occurrence Download

description: A dataset containing 607 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Mycteroperca venenosa (Linnaeus, 1758)",
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 "Year is greater than or equal to 1900"
 ]
}

 The dataset includes 607 records from 66 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0053635-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ahucew
title: Occurrence Download

description: A dataset containing 2144 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Myctophum punctatum Rafinesque, 1810",
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 "Year is greater than or equal to 1900"
 ]
}

 The dataset includes 2144 records from 47 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0053636-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ex8puk
title: Occurrence Download

description: A dataset containing 2927 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Myliobatis aquila (Linnaeus, 1758)",
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 "Year is greater than or equal to 1900"
 ]
}

 The dataset includes 2927 records from 60 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0053637-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.14585929
title: Permutation Test RF Distances
DOI: 10.5281/zenodo.14585930
title: Permutation Test RF Distances
DOI: 10.6084/m9.figshare.25712693
title: A pharmacovigilance study of adverse events associated with polymyxins based on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database

description: Polymyxins have been regarded as last-line treatment for multidrug-resistant gram-negative bacterial infections. Nonetheless, concerns regarding toxicity persist. This study aimed to explore and compare potential adverse events (AEs) between colistin and polymyxin B (PMB). Polymyxins-related AEs were retrieved from the U.S. Food and Drug Administration Adverse Event Reporting System between 2004 and 2022. Potential signals were estimated by the reporting odds ratio (ROR), and subgroup analyses were preformed to adjust for potential factors in AEs with significant disproportionality. Analysis of 3,915 records involving 718 patients revealed a higher disproportionality of renal and urinary disorders (ROR 1.62, 95% CI 1.01–2.59) and acute kidney injury (ROR 1.75, 95% CI 1.07–2.87) with colistin treatment. Conversely, colistin exhibited a lower risk for neurotoxicity (ROR 0.47, 95% CI 0.30–0.73). Seven cases of skin hyperpigmentation were reported with PMB, whereas none were reported with colistin. Over 80% of cases involving polymyxin-related AEs occurred during the first two weeks of therapies, with a median onset time of 4.5 days. Patients received colistin displayed a higher potential risk of nephrotoxicity but a lower risk of neurotoxicity. Clinicians should be vigilant in monitoring the AEs of hyperpigmentation disorders induced by PMB.
DOI: 10.6084/m9.figshare.25712693.v2
title: A pharmacovigilance study of adverse events associated with polymyxins based on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database

description: Polymyxins have been regarded as last-line treatment for multidrug-resistant gram-negative bacterial infections. Nonetheless, concerns regarding toxicity persist. This study aimed to explore and compare potential adverse events (AEs) between colistin and polymyxin B (PMB). Polymyxins-related AEs were retrieved from the U.S. Food and Drug Administration Adverse Event Reporting System between 2004 and 2022. Potential signals were estimated by the reporting odds ratio (ROR), and subgroup analyses were preformed to adjust for potential factors in AEs with significant disproportionality. Analysis of 3,915 records involving 718 patients revealed a higher disproportionality of renal and urinary disorders (ROR 1.62, 95% CI 1.01–2.59) and acute kidney injury (ROR 1.75, 95% CI 1.07–2.87) with colistin treatment. Conversely, colistin exhibited a lower risk for neurotoxicity (ROR 0.47, 95% CI 0.30–0.73). Seven cases of skin hyperpigmentation were reported with PMB, whereas none were reported with colistin. Over 80% of cases involving polymyxin-related AEs occurred during the first two weeks of therapies, with a median onset time of 4.5 days. Patients received colistin displayed a higher potential risk of nephrotoxicity but a lower risk of neurotoxicity. Clinicians should be vigilant in monitoring the AEs of hyperpigmentation disorders induced by PMB.
DOI: 10.6084/m9.figshare.28033476
title: The cell replacement therapeutic potential of human pluripotent stem cells

description: The remarkable ability of human pluripotent stem cells (hPSCs) to differentiate into specialized cells of the human body emphasizes their immense potential in treating various diseases. Advances in hPSC technology are paving the way for personalized and allogeneic cell-based therapies. The first-in-human studies showed improved treatment of diseases with no adverse effects, which encouraged the industrial production of this type of medicine. To ensure the quality, safety and efficacy of hPSC-based products throughout their life cycle, it is important to monitor and control their clinical translation through good practices (GxP) regulations. Understanding these rules in advance will help ensure that the industrial development of hPSC-derived products for widespread clinical implementation is feasible and progresses rapidly. In this review, we discuss the key translational obstacles of hPSCs, outline the current hPSC-based clinical trials, and present a workflow for putative clinical hPSC-based products. Finally, we highlight some future therapeutic opportunities for hPSC-derivatives. hPSC-based products continue to show promise for the treatment of a variety of diseases. While clinical trials support the relative safety and efficacy of hPSC-based products, further investigation is required to explore the clinical challenges and achieve exclusive regulations for hPSC-based cell therapies.
DOI: 10.6084/m9.figshare.28033476.v1
title: The cell replacement therapeutic potential of human pluripotent stem cells

description: The remarkable ability of human pluripotent stem cells (hPSCs) to differentiate into specialized cells of the human body emphasizes their immense potential in treating various diseases. Advances in hPSC technology are paving the way for personalized and allogeneic cell-based therapies. The first-in-human studies showed improved treatment of diseases with no adverse effects, which encouraged the industrial production of this type of medicine. To ensure the quality, safety and efficacy of hPSC-based products throughout their life cycle, it is important to monitor and control their clinical translation through good practices (GxP) regulations. Understanding these rules in advance will help ensure that the industrial development of hPSC-derived products for widespread clinical implementation is feasible and progresses rapidly. In this review, we discuss the key translational obstacles of hPSCs, outline the current hPSC-based clinical trials, and present a workflow for putative clinical hPSC-based products. Finally, we highlight some future therapeutic opportunities for hPSC-derivatives. hPSC-based products continue to show promise for the treatment of a variety of diseases. While clinical trials support the relative safety and efficacy of hPSC-based products, further investigation is required to explore the clinical challenges and achieve exclusive regulations for hPSC-based cell therapies.
DOI: 10.6084/m9.figshare.25712693.v1
title: A Pharmacovigilance Study of adverse events associated with polymyxins based on the U.S. Food and Drug Administration adverse event reporting system (FAERS) database

description: Polymyxins, including both colistin and polymyxin B (PMB), have regained clinical attention as last-line treatment options for treating infections caused by multidrug-resistant (MDR) gram-negative bacteria. Nonetheless, concerns persist regarding the toxicity associated with polymyxins. The objective of this study was to explore the potential severe adverse events (AEs) associated with polymyxins and compare the disparities in AEs between these two agents. Records of AEs associated with colistin and PMB were retrieved from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) from 1 January 2004, to 31 December 2022. Disproportionality analyses using the reporting odds ratio (ROR) method were conducted to estimate the potential risk signals between a specific AE and a drug, from the High-Level Term (HLT) to the System Organ Class (SOC) level. Subgroup analyses were performed to adjust for potential factors in each HLT with a significant disproportionality. A total of 3,915 records involving 718 patients were analyzed for the utilization of colistin and PMB. Apart from the effects on the renal and blood systems, the disproportionality strength between the two agents varied significantly in several other organs and systems, including the skin and cardiovascular and nervous systems. Our findings revealed a higher disproportionality of renal and urinary disorders (ROR 1.62, 95% CI 1.01-2.59) and acute kidney injury (AKI) (ROR 1.75, 95% CI 1.07-2.87) in patients treated with colistin. Conversely, colistin exhibited a lower potential risk for inducing neurotoxicity when compared to PMB (ROR 0.47, 95% CI 0.30-0.73). Notably, seven cases of skin hyperpigmentation (SH) associated with intravenous PMB have been reported, whereas none have been reported with colistin. Over 80% of cases involving polymyxin-related AEs occurred during the first two weeks following the initiation of polymyxin therapies, with a median onset time of 4.5 days. No difference was observed in the time of onset of AEs between colistin and PMB. Patients treated with colistin displayed a higher potential risk of nephrotoxicity but a lower risk of neurotoxicity when compared to those treated with PMB. Clinicians should be vigilant in monitoring the AEs of hyperpigmentation disorders induced by PMB, as there have been reported cases associated with its use, whereas no instances of this AE were reported among colistin-treated patients. Nevertheless, further research, especially with larger sample sizes, is imperative to validate these findings.
DOI: 10.6084/m9.figshare.26414530
title: A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS)

description: The FDA Adverse Event Reporting System (FAERS) was used to mine and evaluate adverse events (AEs) associated with cyclin-dependent kinase (CDK) 4/6 inhibitors, thereby providing a reference for clinical rational drug use. AE data related to CDK4/6 inhibitors from the first quarter of 2015 to the first quarter of 2023 were acquired from FAERS, while the signal mining was processed using the reporting odds ratio (ROR) method and Bayesian confidence propagation neural network (BCPNN) method. The number of AE reports for CDK4/6 inhibitors was, respectively, 132,494 for palbociclib, 56,151 for ribociclib, and 7,014 for abemaciclib. The corresponding numbers of AE signals were 322,522, and 59, with the number of involved System Organ Class (SOC) being 23, 23, and 15, mainly involving blood and lymphatic system disorders, respiratory, thoracic and mediastinal disorders, hepatobiliary disorders, skin and subcutaneous tissue disorders, etc. CDK4/6 inhibitors could lead to pulmonary toxicity, myelosuppression, skin reactions, etc. Special attention should be paid to abemaciclib for interstitial lung disease (ILD), erythema multiforme, and thrombosis risk; ribociclib for cardiac toxicity, hepatotoxicity, and musculoskeletal toxicity; palbociclib for neurocognitive impairment and osteonecrosis of the jaw.
DOI: 10.6084/m9.figshare.26414530.v3
title: A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS)

description: The FDA Adverse Event Reporting System (FAERS) was used to mine and evaluate adverse events (AEs) associated with cyclin-dependent kinase (CDK) 4/6 inhibitors, thereby providing a reference for clinical rational drug use. AE data related to CDK4/6 inhibitors from the first quarter of 2015 to the first quarter of 2023 were acquired from FAERS, while the signal mining was processed using the reporting odds ratio (ROR) method and Bayesian confidence propagation neural network (BCPNN) method. The number of AE reports for CDK4/6 inhibitors was, respectively, 132,494 for palbociclib, 56,151 for ribociclib, and 7,014 for abemaciclib. The corresponding numbers of AE signals were 322,522, and 59, with the number of involved System Organ Class (SOC) being 23, 23, and 15, mainly involving blood and lymphatic system disorders, respiratory, thoracic and mediastinal disorders, hepatobiliary disorders, skin and subcutaneous tissue disorders, etc. CDK4/6 inhibitors could lead to pulmonary toxicity, myelosuppression, skin reactions, etc. Special attention should be paid to abemaciclib for interstitial lung disease (ILD), erythema multiforme, and thrombosis risk; ribociclib for cardiac toxicity, hepatotoxicity, and musculoskeletal toxicity; palbociclib for neurocognitive impairment and osteonecrosis of the jaw.